Enzyvant Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Enzyvant's estimated annual revenue is currently $4.2M per year.(i)
  • Enzyvant's estimated revenue per employee is $155,000

Employee Data

  • Enzyvant has 27 Employees.(i)
  • Enzyvant grew their employee count by -53% last year.

Enzyvant's People

NameTitleEmail/Phone
1
VP, Head Program & Portfolio Management, EnzyvantReveal Email/Phone
2
SVP, Head Early-Stage Development and PartneringReveal Email/Phone
3
SVP, CMCReveal Email/Phone
4
SVP, Platform Head for T-Cell GenerationReveal Email/Phone
5
VP, Head Finance / Acting CFOReveal Email/Phone
6
SVP, Regulatory Affairs, Pharmacovigilance, and QualityReveal Email/Phone
7
VP, Clinical DevelopmentReveal Email/Phone
8
SVP, CMCReveal Email/Phone
9
Chief Medical OfficerReveal Email/Phone
10
DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Enzyvant?

About Enzyvant Enzyvant is a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases. Enzyvant's lead asset is the investigational tissue-based regenerative therapy, RVT-802, for congenital athymia, an ultra-rare and life-threatening pediatric immunodeficiency. RVT-802 has been granted multiple regulatory designations, including the US Food and Drug Administration expedited designation as a Regenerative Medicine Advanced Therapy (RMAT). Enzyvant is part of Sumitovant Biopharma (wholly owned by Sumitomo Dainippon Pharma), a global ecosystem of companies working on innovative research and development activities to transform healthcare and improve the lives of people worldwide. This global ecosystem has a geographic footprint spanning Japan, the US, China and the EU as well as talent, knowledge and resources across a wide spectrum of technologies and therapeutic areas.

keywords:N/A

N/A

Total Funding

27

Number of Employees

$4.2M

Revenue (est)

-53%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Enzyvant News

2022-04-19 - Enzyvant to build regenerative medicine manufacturing plant in North Carolina

Enzyvant, which focuses on developing regenerative medicines for rare diseases, has laid out plans to build a.

2022-04-19 - Another new manufacturing site for NC; BioCentriq acquired ...

Sumitomo will codevelop the site with Enzyvant. BioCentriq acquired by South Korean company. GC has signed a deal to acquire New Jersey-based...

2022-04-19 - Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities

CAMBRIDGE, Mass. and BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- Enzyvant, a commercial-stage biotechnology company with a focus...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.5M27-64%$151.3M
#2
$2.7M27N/AN/A
#3
$1.9M27-7%$5M
#4
$4.2M274%N/A
#5
$3.5M278%N/A